Clinical Trial

The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

Name: The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy — clinical trial record (NCT06614985)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TEST-T-PMN

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multiple-center, prospective, open-label, positive drug controlled, randomized, clinical study to evaluate the safety and efficacy of Telitacicept in the treatment of primary membranous nephropathy.

Trial Details

NCT Number	NCT06614985
Lead Sponsor	Renmin Hospital of Wuhan University
Conditions	Primary Membranous Nephropathy
Enrollment	172 participants
Start Date	2024-10-20
Primary Completion	2026-10-01 (estimated)
Study Completion	2027-10-01 (estimated)
Updated on ClinicalTrials.gov	2024-09-26